Abstract
Invasive fungal disease (IFD) is becoming more prevalent in transplant and oncology patients as a result of the potent immunosuppressive therapies used to prevent allograft rejection and/or the use of cytotoxic chemotherapy to treat cancer. Mortality attributable to IFD remains high despite advances in antifungal therapies. There is a continued need for laboratory diagnostics to help improve clinical outcomes. In recent years, culture-based detection strategies and histopathology have been supplemented with molecular and proteomic techniques as well as antigen detection methods. Refinements in these assays are improving the diagnosis of IFD, with the greatest strides made within the molecular and proteomic arenas. This review highlights recent laboratory developments in the diagnosis of invasive candidiasis, cryptococcosis, opportunistic molds, and endemic fungal infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
